Methods and compositions for treating Huntington's disease
Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.
1. A non-naturally occurring zinc finger protein comprising 6 zinc finger domains ordered F1 to F6, respectively, wherein the zinc finger protein specifically binds to mutant Huntington's gene allele (mHtt) gene and comprises the recognition helix regions as follows:
(SEQ ID NO: 60)
F1: RSDNLSE;
(SEQ ID NO: 61)
F2: KRCNLRC;
(SEQ ID NO: 18)
F3: QSGDLTR;
(SEQ ID NO: 18)
F4: QSGDLTR;
(SEQ ID NO: 60)
F5: RSDNLSE;
and
(SEQ ID NO: 61)
F6: KRCNLRC.
2. The zinc finger protein of claim 1 , wherein the zinc finger protein binds to sequences within the CAG repeat region of the mHtt gene.
3. A host cell comprising one or more zinc finger proteins of claim 1 .
4. A pharmaceutical composition comprising one or more zinc finger proteins according to claim 1 .
5. A fusion protein comprising a zinc finger protein of claim 1 and a transcriptional repression domain.
6. A method of modifying expression of an mHtt gene in a cell, the method comprising administering to the cell one or more polynucleotides encoding one or more fusion proteins according to claim 5 .
7. A polynucleotide encoding one or more fusion proteins according to claim 5 .
8. A pharmaceutical composition comprising one or more polynucleotides according to claim 7 .
9. A method of treating Huntington's Disease, the method comprising administering one or more polynucleotides according to claim 7 to a subject in need thereof.
10. An AAV vector comprising the polynucleotide of claim 7 .
11. The AAV vector of claim 10 , wherein the AAV vector is an AAV6 or AAV9 vector.
12. A pharmaceutical composition comprising one or more AAV vectors according to claim 10 .
13. A method of treating Huntington's Disease, the method comprising administering one or more AAV vectors according to claim 10 to a subject in need thereof.